Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05241834 · ClinicalTrials.gov registry record · Phase 1

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 1
Development phase
70
Enrollment target
16
Study locations

NCT05241834 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 70 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05241834, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
16
Study locations

Study Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Conditions Studied

Carcinoma, Non-Small Cell Lung Thyroid Neoplasms

Interventions

  • DRUG LOXO-260

Study Locations (16)

California

  • UCLA Medical Center - Los Angeles
  • UCSF Medical Center at Mission Bay - San Francisco

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Ohio

  • Cleveland Clinic Foundation - Cleveland
  • Ohio State University Hospital - Columbus

Other

  • Centre Leon Berard - Lyon
  • Institut Gustave Roussy (Igr) - Villejuif

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago Medicine-Comprehensive Cancer Center - Chicago

Michigan

  • University of Michigan - Ann Arbor

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2022-03-23
Est. Completion 2026-06
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05241834

The ClinicalTrials.gov registry entry for NCT05241834 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which LOXO-260 is the first listed.

NCT05241834 reports 16 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, Ohio.

Frequently Asked Questions

What is clinical trial NCT05241834 about?

NCT05241834 is a clinical study titled "A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment". The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease do...

What is the current status of trial NCT05241834?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2022-03-23. Estimated completion is 2026-06.

What conditions does trial NCT05241834 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Thyroid Neoplasms.

What interventions are being tested in trial NCT05241834?

The interventions under investigation include: LOXO-260 (DRUG).

Who is sponsoring clinical trial NCT05241834?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05241834 being conducted?

This trial has 16 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Thyroid Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.